CRISPR Therapeutics co-founder uncloaks an off-the-shelf cell therapy startup with $87M and a lot of fanfare
When Chad Cowan was recruited to Harvard University 20 years ago to work on human embryonic stem cells, he was inspired by the idea that these specialized cells could be used to make insulin-producing beta cells and potentially cure Type 1 diabetes.
However, he soon realized if those cells were going to do it, they would need to overcome the immune response that the body naturally mounts against foreign bodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.